<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Pharmacol</journal-id><journal-id journal-id-type="publisher-id">IJPharm</journal-id><journal-title-group><journal-title>Indian Journal of Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0253-7613</issn><issn pub-type="epub">1998-3751</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25821315</article-id><article-id pub-id-type="pmc">4375823</article-id><article-id pub-id-type="publisher-id">IJPharm-47-72</article-id><article-id pub-id-type="doi">10.4103/0253-7613.150347</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Safety and efficacy of Qurse-e-istisqua in chronic hepatitis C Infection: An exploratory study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rehan</surname><given-names>Harmeet Singh</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Chopra</surname><given-names>Deepti</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Yadav</surname><given-names>Madhur</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Wardhan</surname><given-names>Neeta</given-names></name><xref ref-type="aff" rid="aff4">3</xref></contrib><contrib contrib-type="author"><name><surname>Manak</surname><given-names>Seema</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Siddiqui</surname><given-names>KM</given-names></name><xref ref-type="aff" rid="aff5">4</xref></contrib><contrib contrib-type="author"><name><surname>Aslam</surname><given-names>Mohd.</given-names></name><xref ref-type="aff" rid="aff6">5</xref></contrib></contrib-group><aff id="aff1">Department of Pharmacology, Lady Hardinge Medical College, New Delhi, India</aff><aff id="aff2"><label>1</label>Department of Pharmacology, HIMSR, Jamia Hamdard, New Delhi, India</aff><aff id="aff3"><label>2</label>Department of Medicine, Lady Hardinge Medical College, New Delhi, India</aff><aff id="aff4"><label>3</label>Department of Pharmacology, University College of Medical Sciences, New Delhi, India</aff><aff id="aff5"><label>4</label>Central Council for Research in Unani Medicines, AYUSH, Ministry of Health and Family Welfare, Janak Puri, New Delhi, India</aff><aff id="aff6"><label>5</label>Department Pharmacology Ilmul Advia, faculty of Unani Medicine, Hamdard University, New Delhi, India</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Dr. Harmeet Singh Rehan, E-mail: <email xlink:href="harmeetrehan@hotmail.com">harmeetrehan@hotmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2015</year></pub-date><volume>47</volume><issue>1</issue><fpage>72</fpage><lpage>79</lpage><history><date date-type="received"><day>11</day><month>9</month><year>2013</year></date><date date-type="rev-recd"><day>24</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>30</day><month>12</month><year>2014</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Pharmacology</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>Qurse-e-istisqua (Q-e-I), an Unani medicine commonly prescribed to treat liver disorders.</p></sec><sec id="st2"><title>Objectives:</title><p>To study efficacy and safety of Q-e-I in hepatitis C virus (HCV) infection.</p></sec><sec id="st3"><title>Methods:</title><p>In this randomized double-blind exploratory study, 60 naive patients of HCV infection were assigned to receive either interferon&#x003b1;2a (IFN&#x003b1;2a) (3 mIU, subcutaneous, thrice weekly), ribavirin (RBV) (1000 mg, orally, twice daily in divided doses) and placebo (<italic>n</italic> = 30) or IFN&#x003b1;2a, RBV and Q-e-I (5 g, orally, thrice daily in divided doses) (<italic>n</italic> = 30). HCV RNA levels, serum hyaluronic acid (SHA), ultrasound image scoring for fibrosis, liver and renal function test, prothrombin time, were done at the baseline and thereafter periodically.</p></sec><sec id="st4"><title>Results:</title><p>Early virologic response (EVR), end of treatment response (ETR) and sustained virologic response (SVR) were 90%, 96.6% and 90% in the control group and 86.6%, 90.0% and 83.3% in the treatment group. SHA level was lower in the treatment group at the end of the treatment as compared to the control group. Mean end of follow-up ultrasound image scoring for fibrosis in the control and the treatment group was 1.37 &#x000b1; 0.07 and 1.22 &#x000b1; 0.06 respectively. Aspartate aminotransferase (AST) levels were significantly lower in the treatment group than the control group at 1-month. Commonly observed adverse drug reactions included fever, hair fall, fatigue, anemia, and diarrhea.</p></sec><sec id="st5"><title>Conclusion:</title><p>Q-e-I was well tolerated and showed anti-fibrotic activity. EVR, ETR and SVR suggested that Q-e-I do not have any anti-HCV activity. Early recovery in AST and inhibition of progress of fibrosis in Q-e-I group was probably due to the anti-inflammatory and antioxidant activity of its ingredients.</p></sec></abstract><kwd-group><title>KEY WORDS</title><kwd>Fibrosis</kwd><kwd>hepatitis C</kwd><kwd>interferon</kwd><kwd>Qurse-e-istisqua</kwd><kwd>ribavirin</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>Introduction</title><p>Hepatitis C is an escalating health burden worldwide. Global prevalence of hepatitis C virus (HCV) infection is around 2%, with 170 million persons chronically infected with the virus.[<xref rid="ref1" ref-type="bibr">1</xref>] In India, seroprevalence in the community has been reported to be 0.87% whereas it is 1.8&#x02013;2.5% among the blood donor population.[<xref rid="ref2" ref-type="bibr">2</xref>] Majority (50&#x02013;80%) of those infected with acute infection with HCV develop chronic infection that rarely resolves spontaneously. Chronic hepatitis C infection is associated with multiple complications such as hepatic fibrosis, cirrhosis and hepatocellular carcinoma.[<xref rid="ref3" ref-type="bibr">3</xref>]</p><p>The currently recommended treatment options for the hepatitis C infection include interferon (INF) in combination with ribavirin that is associated with limitations like adverse effects, high cost, and inconvenience in administering injections. Complementary alternative medicines (CAM) viz. silymarin, glycyrrhizin are popular amongst patients with liver disorders as hepatoprotective agents[<xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref>] and have shown biochemical and immunological benefits.[<xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>]</p><p>Qurse-e-istisqua (Q-e-I) is a polyherbal formulation of Unani system of medicine containing <italic>Nardostachys jatamansi</italic>, <italic>Cucumis sativus</italic>, <italic>Portulacea olenlcea</italic>, <italic>Cuscuta reflexa roxb</italic>, <italic>Apium graveolens</italic>, <italic>Pistacia lentiscus</italic>, <italic>Berry</italic>, <italic>Rheum emodi</italic>, <italic>Rosa damascena</italic>, <italic>Berberis aristata</italic>, <italic>Intibus satibus</italic> and <italic>Solanum nigrum</italic>, which has been approved for hepatitis diseases.[<xref rid="ref8" ref-type="bibr">8</xref>] In experimental studies, some of the constituents of Q-e-I <italic>viz N. jatamansi</italic>, <italic>A. graveolens</italic> linn, <italic>R. emodi</italic>, <italic>B. aristata</italic> and <italic>S. nigrum</italic> linn have shown antioxidant, antifibrotic and hepatoprotective activity.[<xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref10" ref-type="bibr">10</xref><xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref>] There is no clinical evidence for the use of Q-e-I in literature; hence the present clinical study was designed to evaluate the efficacy and safety of Q-e-I in hepatitis C patients as an adjuvant to the conventional therapy.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>Materials and Methods</title><p>This prospective, randomized, double-blind exploratory study was conducted in the Department of Pharmacology and Department of Medicine, Lady Hardinge Medical College and associated SSK Hospital, New Delhi. HCV-RNA positive patients aged 18&#x02013;60 years, of either sex, were included in the study. The exclusion criteria were; History of treatment with conventional INF, pegylated INF or ribavirin (RBV) less than 6 months prior to enrolment, creatinine levels above 150 &#x003bc;mol/l, hemoglobin levels below 10 g/dl, white blood cell count below 3 &#x000d7; 10<sup>9</sup>/l, platelet count below 1 &#x000d7; 10<sup>11</sup>/l; history of varices, ascites, encephalopathy, decompensated liver disease, active co-infection with HBV, history of any systemic anticancer or immune modulatory treatment 6 months prior to enrolment. Patients who used alcohol, any other anti-viral medication during the trial, pregnant women, lactating women, having history of hepatic, renal, or other major organ transplantation were also excluded from the study.</p><p>Study protocol was approved by the Institutional Ethics Committee. Informed consent was taken from all the patients. A physician of Unani system of medicine was designated as co-principal investigator. Enrolled patients were randomly assigned to receive either conventional INF&#x003b1;2a (3 MIU, subcutaneously, thrice weekly), RBV (1000 mg, orally, daily, in two divided doses) and placebo (in three divided doses) (control group) or conventional INF&#x003b1;2a, RBV and Q-e-I (5 g, orally, daily, in three divided doses) (test group). Duration of treatment for HCV infection with genotype 1 and 4 was 48 weeks and with genotype 2 and 3 was 24 weeks. For mixed HCV infections, duration of treatment was in accordance to the genotype requiring treatment for longer duration. After completion of treatment, patients were followed for a period of 24 weeks. Computer generated allocation sequence was used for randomization of subjects. Investigator and patients were masked to the treatment assignment. Placebo was made identical to the test drug in terms of shape, size, color and weight.</p><p>Complete blood count (CBC), liver function test, renal function test, prothrombin time (PT) and partial prothrombin time (PTTK) were done at baseline and at 4, 12, 24 and 48wks (for genotype 1 and 4). CBC was also carried out at 2 weeks. Baseline Anti HCV antibody, HCV RNA level, HCV genotype and HBs Ag were determined. HCV RNA levels were repeated at 12 weeks, 24 weeks (genotype 2 and 3), 48 weeks (genotype 1 and 4) and 6 months after completion of treatment in both the groups.</p><p>To evaluate the extent of fibrosis of liver serum hyaluronic acid was determined using ELISA at baseline and at the end of the therapy,[<xref rid="ref14" ref-type="bibr">14</xref>] and ultrasound imaging of liver was done at baseline 4, 8, 12, 16 weeks, end of the treatment and end of the follow-up.[<xref rid="ref15" ref-type="bibr">15</xref>]</p><p>Efficacy of treatment was determined by estimating the early virologic response (EVR), End-of-treatment response (ETR) and Sustained virologic response (SVR). EVR was defined as &#x0003e;2 log reduction in HCV RNA level as compared to the baseline by 12 weeks (partial EVR) or HCV RNA not detectable at treatment week 12 (complete EVR). ETR was considered when HCV RNA was not detected in the blood at the end of treatment, which is 48 weeks for genotype 1 and 24 weeks for other genotypes. SVR was considered when HCV RNA remained negative for 24 weeks after the cessation of treatment.[<xref rid="ref16" ref-type="bibr">16</xref>]</p><p>Causality assessment of adverse drug reactions was performed using Naranjo probability scale.[<xref rid="ref17" ref-type="bibr">17</xref>]</p><sec id="sec2-1"><title/><sec id="sec3-1"><title>Statistical Analysis</title><p>Student's <italic>t</italic>-test (paired and unpaired) was used to analyze the data, and Chi-square test was used for comparing the proportions. <italic>P</italic> &#x0003c; 0.05 was considered statistically significant.</p></sec></sec></sec><sec sec-type="results" id="sec1-3"><title>Results</title><sec id="sec2-2"><title/><sec id="sec3-2"><title>Study Population</title><p>A total of one hundred and two patients were screened, out of which seventy-six patients were enrolled in the study. Eight patients in the control group and 8 patients in the test group dropped out from a study on their own without giving reasons. Sixty patients completed the study [<xref ref-type="fig" rid="F1">Figure 1</xref>]. Majority of patients were men 25 (83.3%) in the control group and 24 (80%) in the test group. Mean age of the patients in both the groups was comparable that is, 31.0 &#x000b1; 1.29 years in the control and 36.9 &#x000b1; 2.0 years in the test group. Body weight of the patients in both the groups was also similar that is, 64 &#x000b1; 8.3 kg in the control and 62 &#x000b1; 10.4 kg in the test group [<xref ref-type="table" rid="T1">Table 1</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Recruitment of patients</p></caption><graphic xlink:href="IJPharm-47-72-g001"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Demographic characteristics of the study population</p></caption><graphic xlink:href="IJPharm-47-72-g002"/></table-wrap></sec><sec id="sec3-3"><title>Efficacy Assessment</title></sec><sec id="sec3-4"><title>Viral load</title><p>Overall EVR was achieved by 53 of 60 patients; 27 (90%) in the control group and 26 (86.6%) in the test group. This was statistically insignificant (difference 3.4%; 95% confidence interval [CI], &#x02212;0.12 to &#x02212;0.19; <italic>P</italic> = 0.68) [<xref ref-type="table" rid="T2">Table 2</xref>]. Overall, the majority of the patients obtained a complete EVR while the number of those obtained a partial EVR was 3 of 60 patients (05%) with the no difference between the two groups [<xref ref-type="table" rid="T2">Table 2</xref>].</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Virological response of the patients</p></caption><graphic xlink:href="IJPharm-47-72-g003"/></table-wrap><p>Overall EVR in sum total of genotype 1 and 4 was observed in 11 of 16 patients; 5 of 7 patients (71.4%) in the control group and 6 of 9 patients (66.6%) in the test group. The difference was statistically insignificant (difference, 4.8%; 95% CI, &#x02212;0.41 to &#x02212;0.50; <italic>P</italic> = 0.83) [<xref ref-type="table" rid="T2">Table 2</xref>].</p><p>Overall, EVR in genotype 3 was observed in 39 of 41 patients; 21 of 22 patients in (95.45%) in the control group and 18 of 19 patients (94.5%) in the test group. There was no patient with genotype 2. The difference was statistically insignificant (difference, 0.9%; 95% CI, &#x02212;0.125 to &#x02212;0.144; <italic>P</italic> = 0.91) [<xref ref-type="table" rid="T2">Table 2</xref>].</p><p>Overall, ETR was obtained in 56 patients (93.3%); 29 of 30 patients (96.6%) in control group and 27 of 30 patients (90.0%) in test group (difference, 3.3%; 95% CI, &#x02212;0.59 to &#x02212;0.191; <italic>P</italic> = 0.60) [<xref ref-type="table" rid="T2">Table 2</xref>].</p><p>Overall ETR in sum total of genotype 1 and 4 was observed in 14 of 16 patients; 7 of 7 patients in (100%) in the control group and 7 of 9 patients (77.7%) in the test group. The difference was statistically insignificant (difference, 22.3%; 95% CI, &#x02212;0.048 to &#x02212;0.49; <italic>P</italic> = 0.5) [<xref ref-type="table" rid="T2">Table 2</xref>].</p><p>Overall ETR in genotype 3 was observed in 39 of 41 patients; 21 of 22 patients in (95.45%) in the control group and 18 of 19 patients (94.5%) in the test group. The difference was statistically insignificant (Difference 0.9%; 95% CI, &#x02212;0.125 to &#x02212;0.144; <italic>P</italic> = 0.9) [<xref ref-type="table" rid="T2">Table 2</xref>].</p><p>Overall, a SVR was obtained in 52 of 60 patients (86.6%); 27 of 30 (90%) in control group and 25 of 30 (83.3%) in the test group (difference, 6.7%; 95% CI, &#x02212;0.104 to &#x02212;0.238; <italic>P</italic> = 0.70) [<xref ref-type="table" rid="T2">Table 2</xref>].</p><p>SVR in sum total of genotype 1 and 4 was obtained in 13 of the 16 patients (81.25%); 6 of 7 patients (85.7%) in control group and 7 of the 9 patients (77.7%) in test group. The difference between the two groups was statistically insignificant (difference, 4.5%, 95% CI, &#x02212;0.29 to &#x02212;0.455; <italic>P</italic> = 0.68) [<xref ref-type="table" rid="T2">Table 2</xref>].</p><p>SVR in genotype 3 was obtained in 36 of the 41 patients (87.8%); 20 of 22 patients (90.9%) in control group and 16 of the 19 patients (84.2%) in test group. The difference between the two groups was statistically insignificant (difference, 6.7%; 95% CI, &#x02212;0.28 to &#x02212; 0.13; <italic>P</italic> = 0.86) [<xref ref-type="table" rid="T2">Table 2</xref>].</p><p>A total of 3 of 41 (7.3%) patients with genotype 2 or 3 experienced a relapse during follow-up; including 1 of 22 (4.5%) patients in the control group and 2 of 19 (10.5%) in the test group.(Difference, 6%; 95% CI, &#x02212;0.09 to &#x02212; 0.25; <italic>P</italic> = 0.8). One of the 16 (6.25%) patients with genotype 1 and 4 experienced a relapse during follow-up [<xref ref-type="table" rid="T2">Table 2</xref>].</p></sec><sec id="sec3-5"><title>Anti-fibrotic activity</title><p>Mean baseline ultrasound image scoring for fibrosis in control and test group was 1.3 &#x000b1; 0.08 and 1.37 &#x000b1; 0.49 respectively. In the control group, fibrotic score remained unchanged throughout the treatment while in the test group, fibrotic score reduced significantly at 4 month (<italic>P</italic> &#x0003c; 0.05) and thereafter remained lower than the baseline at the end of the treatment and follow-up [<xref ref-type="fig" rid="F2">Figure 2</xref>].</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Ultrasound image scoring for liver fibrosis (mean &#x000b1; standard error mean) at baseline 1, 2, 3, 4 months, end of treatment and at the end of follow-up. *<italic>P</italic> &#x0003c; 0.05 - comparison within the groups</p></caption><graphic xlink:href="IJPharm-47-72-g004"/></fig><p>Mean baseline hyaluronic acid in control and test group was 103.1 &#x000b1; 4.38 ng/ml and 111.8 &#x000b1; 5.35 ng/ml respectively. In the control group, it increased significantly to 134.0 &#x000b1; 6.9 ng/ml (<italic>P</italic> &#x0003c; 0.001) at the end of the treatment, whereas it remained unchanged in the test group. On comparing the two groups, the hyaluronic acid levels were significantly lower in the test group [<xref ref-type="fig" rid="F3">Figure 3</xref>].</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>Serum hyaluronic acid levels (mean &#x000b1; standard error mean) at baseline and at the end of treatment. ***<italic>P</italic> &#x0003c; 0.001 comparison within the groups, <sup>&#x02020;&#x02020;</sup><italic>P</italic> &#x0003c; 0.01 - comparison in between the groups</p></caption><graphic xlink:href="IJPharm-47-72-g005"/></fig></sec><sec id="sec3-6"><title>Hematological and biochemical response</title><p>At the end of the treatment, mean hemoglobin level in the test group was to 11.78 &#x000b1; 0.22 g/dl as compared to 11.74 &#x000b1; 0.28 g/dl in the control group. Significant fall in hemoglobin level in both the groups was seen throughout the treatment and end of the follow-up, but this fall in hemoglobin level was insignificantly less in the test group [<xref ref-type="table" rid="T3">Table 3</xref>].</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Hematological and biochemical parameters (mean&#x000b1;SEM)</p></caption><graphic xlink:href="IJPharm-47-72-g006"/></table-wrap><p>On starting the treatment in both the groups TLC reduced, though it remained within normal limits. Reduction in TLC was significant (<italic>P</italic> &#x0003c; 0.001) at 3 months and end of the treatment in the control group while the rate of fall of TLC was lesser in the test group.</p><p>Within the groups significant improvement in aspartate aminotransferase (AST) (<italic>P</italic> &#x0003c; 0.01) and alanine aminotransferase (ALT) (<italic>P</italic> &#x0003c; 0.001) was observed at 1-month and till the end of the follow-up (<italic>P</italic> &#x0003c; 0.001) in the test group while in the control group significant improvement in AST [<xref ref-type="fig" rid="F4">Figure 4</xref>] and ALT [<xref ref-type="fig" rid="F5">Figure 5</xref>] levels was seen at 3 months (<italic>P</italic> &#x0003c; 0.001) and till the end of the follow-up. On comparing the two groups, the AST levels at end of 1-month were significantly lower in the test group. But ALT levels in the test group were insignificantly different from the control group. Significant improvement in alkaline phosphatase (ALP) [<xref ref-type="fig" rid="F6">Figure 6</xref>] levels was seen in both the groups at the end of the treatment and also at the end of the follow-up. No significant difference was seen in the total bilirubin levels in both the groups [<xref ref-type="fig" rid="F7">Figure 7</xref>].</p><fig id="F4" position="float"><label>Figure 4</label><caption><p>Serum alkaline phosphatase levels (mean &#x000b1; standard error mean) at baseline, 1-month, 3 months, end of treatment and at end of follow-up. **<italic>P</italic> &#x0003c; 0.01, ***<italic>P</italic> &#x0003c; 0.001 comparison within the groups</p></caption><graphic xlink:href="IJPharm-47-72-g007"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><p>Serum aspartate aminotransferase levels (mean &#x000b1; standard error mean) baseline, 1 month, 3 month, end of treatment and at the end of follow-up. ** <italic>P</italic> &#x0003c; 0.01, ***<italic>P</italic> &#x0003c; 0.001 comparison within the groups, <sup>&#x02020;&#x02020;&#x02020;</sup><italic>P</italic> &#x0003c; 0.001 comparison in between the groups</p></caption><graphic xlink:href="IJPharm-47-72-g008"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><p>Serum alanine aminotransferase levels (mean &#x000b1; standard error mean) baseline, 1-month, 3 months, end of treatment and at the end of follow-up. ***<italic>P</italic>&#x0003c;0.001 comparison within the groups, <sup>&#x02020;</sup><italic>P</italic>&#x0003c;0.05 comparison in between the groups</p></caption><graphic xlink:href="IJPharm-47-72-g009"/></fig><fig id="F7" position="float"><label>Figure 7</label><caption><p>Prothrombin time (mean &#x000b1; standard error mean) baseline, 1-month, 3 months, end of treatment and at the end of followup. *<italic>P</italic>&#x0003c;0.05, ***<italic>P</italic>&#x0003c;0.001 comparison within the groups, <sup>&#x02020;</sup><italic>P</italic>&#x0003c;0.05, <sup>&#x02020;&#x02020;&#x02020;</sup><italic>P</italic> &#x0003c; 0.001 comparison in between the groups</p></caption><graphic xlink:href="IJPharm-47-72-g010"/></fig><p>In the control group, mean baseline PT [<xref ref-type="fig" rid="F8">Figure 8</xref>] was 12.33 &#x000b1; 0.13 s. It rose significantly at 1-month (<italic>P</italic> &#x0003c; 0.001) and then reduced significantly at 3 months (<italic>P</italic> &#x0003c; 0.001) and then increased beyond normal limit to 16.23 &#x000b1; 1.57 s (<italic>P</italic> &#x0003c; 0.05) at the end of the treatment. Rise in PT was higher in the control as compared to the test group. In the test group, mean baseline PT was 12.96 &#x000b1; 0.32 s. PT remained similar throughout the treatment and at the end of the treatment. Intergroup comparison also suggested significantly lower PT value (12.7 &#x000b1; 0.23 s) at the end of 1-month and at the end of the treatment (12.86 &#x000b1; 0.52 s).</p><fig id="F8" position="float"><label>Figure 8</label><caption><p>Partial thromboplastin time (mean &#x000b1; standard error mean) baseline, 1-month, 3 months, end of treatment and at the end of follow-up. *<italic>P</italic> &#x0003c; 0.05, ***<italic>P</italic>&#x0003c;0.001 comparison within the groups</p></caption><graphic xlink:href="IJPharm-47-72-g011"/></fig><p>Mean baseline PTTK [<xref ref-type="fig" rid="F9">Figure 9</xref>] in both the groups was within the normal limits. In control group after 3 months of the treatment PTTK value increased significantly (<italic>P</italic> &#x0003c; 0.05), whereas in the test group PTTK values remained similar throughout the treatment.</p><fig id="F9" position="float"><label>Figure 9</label><caption><p>Total bilirubin levels (mean &#x000b1; standard error mean) baseline, 1-month, 3 months, end of treatment and at the end of follow-up</p></caption><graphic xlink:href="IJPharm-47-72-g012"/></fig></sec><sec id="sec3-7"><title>Safety and tolerability</title><p>Of the reported 174 adverse events, 91 were in the control group and 83 in the test group. Causality assessment of the adverse reactions was possible or probable to INF and RBV. Hair fall was significantly (<italic>P</italic> &#x0003c; 0.02) lower in the test group [<xref ref-type="table" rid="T4">Table 4</xref>]. Reduction in hemoglobin levels was observed in all the patients in both the groups but episode of significant anemia (hemoglobin level &#x0003c;10 g% or symptomatic anemia) occurred in 10 of the 30 patients (33%) in control group and 7 of the 30 patients (23.3%) in the test group [<xref ref-type="table" rid="T3">Table 3</xref>]. None of the patient required blood transfusion. One patient was prescribed erythropoietin for severe anemia. Serious adverse events observed during the study were hypothyroidism with pericardial effusion, diminished vision and severe depression with suicidal ideation [<xref ref-type="table" rid="T4">Table 4</xref>].</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Adverse effects of both the treatments</p></caption><graphic xlink:href="IJPharm-47-72-g013"/></table-wrap></sec></sec></sec><sec sec-type="discussion" id="sec1-4"><title>Discussion</title><p>Complementary and alternative medicines like silymarin, glycyrrhizin and St. John's wart are commonly used in patients with chronic liver disease.[<xref rid="ref18" ref-type="bibr">18</xref>] Some of these CAM may have a beneficial effect on liver enzymes, but there is no firm evidence of their efficacy on HCV infection.[<xref rid="ref19" ref-type="bibr">19</xref>] A double-blind study demonstrated SVR in hepatitis C patients receiving the silymarin.[<xref rid="ref20" ref-type="bibr">20</xref>] Adding to this Wagoner <italic>et al</italic>. also reported that purified flavonolignans of silymarin blocked the entry and transmission of HCV in HCV cell culture.[<xref rid="ref21" ref-type="bibr">21</xref>]</p><p>In the present study, EVR, ETR and SVR were similar in patients of genotype 1, 4 and 3 in both the groups and the majority of the patients obtained a complete EVR. This suggested no additional antiviral effect of Q-e-I over standard treatment that is, IFN + RBV. There is no clinical study of Q-e-I available in the literature to compare these findings, but emodin one of the ingredients of Q-e-I, in experimental studies has shown to inhibit HBV DNA replication in HepG2.2.15 <italic>in-vitro</italic> cell culture,[<xref rid="ref22" ref-type="bibr">22</xref>] though its effect needs to be studied against HCV.</p><p>In this study, Q-e-I prevented the progression of fibrosis, it was evident by the reduction in the ultrasound fibrotic score and unchanged levels of hyaluronic acid at the end of the treatment in the test group [Figures <xref ref-type="fig" rid="F2">2</xref> and <xref ref-type="fig" rid="F3">3</xref>]. This effect could be because of the antifibrotic effect of some of the ingredients of Q-e-I viz Nardostchys jatamansi, <italic>R. emodi</italic>, <italic>B. aristata</italic> and <italic>S. nigrum</italic> linn.[<xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref10" ref-type="bibr">10</xref><xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref>]</p><p>Liver enzymes are usually raised in HCV patients. Q-e-I in combination with INF and RBV, significantly reduced the raised levels of ALT (<italic>P</italic> &#x0003c; 0.01), AST (<italic>P</italic> &#x0003c; 0.001) and ALP within the group at the end of 1-month treatment as compared to standard treatment that is, placebo, INF and RBV. Comparing the groups, significant reduction in the AST levels was seen at the 1-month of the treatment. This suggested that the supplementation of Q-e-I can help in early recovery of liver enzymes. The ingredients of Q-e-I in animal studies has shown favorable effects on liver enzymes.[<xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref10" ref-type="bibr">10</xref><xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref>] Other CAMs have also shown the beneficial effect on liver enzymes. Glycyrrhizin given intravenously in patients with chronic HCV infection lowered ALT levels (26% vs. 6% with placebo) within 4 weeks of treatment.[<xref rid="ref23" ref-type="bibr">23</xref>] Vailati <italic>et al</italic>. reported significant decrease in ALT and AST in viral hepatitis patient treated with silymarin.[<xref rid="ref24" ref-type="bibr">24</xref>]</p><p>Interferon-alpha and RBV are known to cause significant side effects and the common ones are flu-like symptoms 41%, anemia, leucopenia 13%, depression 10%, discontinuation of therapy 5% and thyroid abnormality 2%.[<xref rid="ref25" ref-type="bibr">25</xref>] In the present study, 33.3% and 23.3% of the chronic hepatitis C patients had a significant fall in the hemoglobin levels in the control and test group respectively. It occurred probably due to the fact that RBV accumulates in erythrocytes and INF-&#x003b1; causes myelosuppression.[<xref rid="ref26" ref-type="bibr">26</xref><xref rid="ref27" ref-type="bibr">27</xref>] Fall in hemoglobin was transient, and no dose modification was required except one patient who required injection erythropoietin in the Q-e-I group. One patient developed depression with suicidal tendency in the test group, causality assessment of which was probable to INF. This required discontinuation of treatment with INF, RBV and Q-e-I. For this patient fluoxetine (20 mg, PO) was prescribed and showed improvement in the symptoms was within 4 weeks of the treatment and INF and RBV therapy was restarted along with the fluoxetine. Similar case of depression with suicidal tendency has been reported with INF by other workers.[<xref rid="ref28" ref-type="bibr">28</xref>] Though INF do not cross blood brain barrier, it may reach circumventricular organs and exert its effect on central nervous system, which could be the reason for suicidal tendency.[<xref rid="ref29" ref-type="bibr">29</xref><xref rid="ref30" ref-type="bibr">30</xref>]</p></sec><sec id="sec1-5"><title>Limitation of the Study</title><p>Fibroscan could have done been a better investigation to evaluate and assess the extent of the fibrosis of the liver. Ultrasound imaging of liver was done due to the nonavailability of the fibroscan facility at the time of conduct of this study.</p></sec><sec sec-type="conclusion" id="sec1-6"><title>Conclusion</title><p>Data suggest that Q-e-I is unlikely to benefit HCV-RNA levels in chronic hepatitis C patients, but it has therapeutic beneficial effect in preventing the progression of fibrosis and early recovery in liver enzymes. Q-e-I is safe and well-tolerated by the patients.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil.</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> No.</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shepard</surname><given-names>CW</given-names></name><name><surname>Finelli</surname><given-names>L</given-names></name><name><surname>Alter</surname><given-names>MJ</given-names></name></person-group><article-title>Global epidemiology of hepatitis C virus infection</article-title><source>Lancet Infect Dis</source><year>2005</year><volume>5</volume><fpage>558</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">16122679</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>SK</given-names></name><name><surname>Choudhuri</surname><given-names>G</given-names></name></person-group><article-title>Hepatitis C: The Indian scenario</article-title><source>Physicians Dig</source><year>2005</year><volume>14</volume><fpage>46</fpage><lpage>53</lpage></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fattovich</surname><given-names>G</given-names></name><name><surname>Stroffolini</surname><given-names>T</given-names></name><name><surname>Zagni</surname><given-names>I</given-names></name><name><surname>Donato</surname><given-names>F</given-names></name></person-group><article-title>Hepatocellular carcinoma in cirrhosis: Incidence and risk factors</article-title><source>Gastroenterology</source><year>2004</year><volume>127</volume><fpage>S35</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">15508101</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strader</surname><given-names>DB</given-names></name><name><surname>Bacon</surname><given-names>BR</given-names></name><name><surname>Lindsay</surname><given-names>KL</given-names></name><name><surname>La Brecque</surname><given-names>DR</given-names></name><name><surname>Morgan</surname><given-names>T</given-names></name><name><surname>Wright</surname><given-names>EC</given-names></name><etal/></person-group><article-title>Use of complementary and alternative medicine in patients with liver disease</article-title><source>Am J Gastroenterol</source><year>2002</year><volume>97</volume><fpage>2391</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12358262</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seeff</surname><given-names>LB</given-names></name><name><surname>Curto</surname><given-names>TM</given-names></name><name><surname>Szabo</surname><given-names>G</given-names></name><name><surname>Everson</surname><given-names>GT</given-names></name><name><surname>Bonkovsky</surname><given-names>HL</given-names></name><name><surname>Dienstag</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial</article-title><source>Hepatology</source><year>2008</year><volume>47</volume><fpage>605</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">18157835</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coon</surname><given-names>JT</given-names></name><name><surname>Ernst</surname><given-names>E</given-names></name></person-group><article-title>Complementary and alternative therapies in the treatment of chronic hepatitis C: A systematic review</article-title><source>J Hepatol</source><year>2004</year><volume>40</volume><fpage>491</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">15123365</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bean</surname><given-names>P</given-names></name></person-group><article-title>The use of alternative medicine in the treatment of hepatitis C</article-title><source>Am Clin Lab</source><year>2002</year><volume>21</volume><fpage>19</fpage><lpage>21</lpage></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><article-title>National formulary of Unani medicine. Ministry of Health and Family Welfare, Govt of India. Part II</article-title><year>1999</year><fpage>30</fpage></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>S</given-names></name><name><surname>Ansari</surname><given-names>KA</given-names></name><name><surname>Jafry</surname><given-names>MA</given-names></name><name><surname>Kabeer</surname><given-names>H</given-names></name><name><surname>Diwakar</surname><given-names>G</given-names></name></person-group><article-title><italic>Nardostachys jatamansi</italic> protects against liver damage induced by thioacetamide in rats</article-title><source>J Ethnopharmacol</source><year>2000</year><volume>71</volume><fpage>359</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">10940571</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhan</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Emodin on hepatic fibrosis in rats</article-title><source>Chin Med J (Engl)</source><year>2000</year><volume>113</volume><fpage>599</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">11776026</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arosio</surname><given-names>B</given-names></name><name><surname>Gagliano</surname><given-names>N</given-names></name><name><surname>Fusaro</surname><given-names>LM</given-names></name><name><surname>Parmeggiani</surname><given-names>L</given-names></name><name><surname>Tagliabue</surname><given-names>J</given-names></name><name><surname>Galetti</surname><given-names>P</given-names></name><etal/></person-group><article-title>Aloe-Emodin quinone pretreatment reduces acute liver injury induced by carbon tetrachloride</article-title><source>Pharmacol Toxicol</source><year>2000</year><volume>87</volume><fpage>229</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">11129503</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janbaz</surname><given-names>KH</given-names></name><name><surname>Gilani</surname><given-names>AH</given-names></name></person-group><article-title>Studies on preventive and curative effects of berberine on chemical-induced hepatotoxicity in rodents</article-title><source>Fitoterapia</source><year>2000</year><volume>71</volume><fpage>25</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">11449466</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raju</surname><given-names>K</given-names></name><name><surname>Anbuganapathi</surname><given-names>G</given-names></name><name><surname>Gokulakrishnan</surname><given-names>V</given-names></name><name><surname>Rajkapoor</surname><given-names>B</given-names></name><name><surname>Jayakar</surname><given-names>B</given-names></name><name><surname>Manian</surname><given-names>S</given-names></name></person-group><article-title>Effect of dried fruits of <italic>Solanum nigrum</italic> LINN against CCl4-induced hepatic damage in rats</article-title><source>Biol Pharm Bull</source><year>2003</year><volume>26</volume><fpage>1618</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">14600413</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halfon</surname><given-names>P</given-names></name><name><surname>Bourli&#x000e8;re</surname><given-names>M</given-names></name><name><surname>P&#x000e9;naranda</surname><given-names>G</given-names></name><name><surname>Deydier</surname><given-names>R</given-names></name><name><surname>Renou</surname><given-names>C</given-names></name><name><surname>Botta-Fridlund</surname><given-names>D</given-names></name><etal/></person-group><article-title>Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus</article-title><source>Comp Hepatol</source><year>2005</year><volume>4</volume><fpage>6</fpage><pub-id pub-id-type="pmid">16008833</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishiura</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>H</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Matsuoka</surname><given-names>Y</given-names></name><name><surname>Yano</surname><given-names>K</given-names></name><name><surname>Daikoku</surname><given-names>M</given-names></name><etal/></person-group><article-title>Ultrasound evaluation of the fibrosis stage in chronic liver disease by the simultaneous use of low and high frequency probes</article-title><source>Br J Radiol</source><year>2005</year><volume>78</volume><fpage>189</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">15730982</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghany</surname><given-names>MG</given-names></name><name><surname>Strader</surname><given-names>DB</given-names></name><name><surname>Thomas</surname><given-names>DL</given-names></name><name><surname>Seeff</surname><given-names>LB</given-names></name></person-group><article-title>American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: An update</article-title><source>Hepatology</source><year>2009</year><volume>49</volume><fpage>1335</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">19330875</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naranjo</surname><given-names>CA</given-names></name><name><surname>Busto</surname><given-names>U</given-names></name><name><surname>Sellers</surname><given-names>EM</given-names></name><name><surname>Sandor</surname><given-names>P</given-names></name><name><surname>Ruiz</surname><given-names>I</given-names></name><name><surname>Roberts</surname><given-names>EA</given-names></name><etal/></person-group><article-title>A method for estimating the probability of adverse drug reactions</article-title><source>Clin Pharmacol Ther</source><year>1981</year><volume>30</volume><fpage>239</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">7249508</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seeff</surname><given-names>LB</given-names></name><name><surname>Lindsay</surname><given-names>KL</given-names></name><name><surname>Bacon</surname><given-names>BR</given-names></name><name><surname>Kresina</surname><given-names>TF</given-names></name><name><surname>Hoofnagle</surname><given-names>JH</given-names></name></person-group><article-title>Complementary and alternative medicine in chronic liver disease</article-title><source>Hepatology</source><year>2001</year><volume>34</volume><fpage>595</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">11526548</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>JP</given-names></name><name><surname>Manheimer</surname><given-names>E</given-names></name><name><surname>Tsutani</surname><given-names>K</given-names></name><name><surname>Gluud</surname><given-names>C</given-names></name></person-group><article-title>Medicinal herbs for hepatitis C virus infection</article-title><source>Cochrane Database Syst Rev</source><year>2001</year><volume>4</volume><fpage>CD003183</fpage><pub-id pub-id-type="pmid">11687177</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x000e1;r</surname><given-names>A</given-names></name><name><surname>Roth</surname><given-names>E</given-names></name><name><surname>Miseta</surname><given-names>A</given-names></name><name><surname>Heged&#x000fc;s</surname><given-names>G</given-names></name><name><surname>P&#x000e1;r</surname><given-names>G</given-names></name><name><surname>Hunyady</surname><given-names>B</given-names></name><etal/></person-group><article-title>Effects of supplementation with the antioxidant flavonoid, silymarin, in chronic hepatitis C patients treated with peg-interferon+ribavirin. A placebo-controlled double blind study</article-title><source>Orv Hetil</source><year>2009</year><volume>150</volume><fpage>73</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19103558</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagoner</surname><given-names>J</given-names></name><name><surname>Negash</surname><given-names>A</given-names></name><name><surname>Kane</surname><given-names>OJ</given-names></name><name><surname>Martinez</surname><given-names>LE</given-names></name><name><surname>Nahmias</surname><given-names>Y</given-names></name><name><surname>Bourne</surname><given-names>N</given-names></name><etal/></person-group><article-title>Multiple effects of silymarin on the hepatitis C virus lifecycle</article-title><source>Hepatology</source><year>2010</year><volume>51</volume><fpage>1912</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">20512985</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shuangsuo</surname><given-names>D</given-names></name><name><surname>Zhengguo</surname><given-names>Z</given-names></name><name><surname>Yunru</surname><given-names>C</given-names></name><name><surname>Xin</surname><given-names>Z</given-names></name><name><surname>Baofeng</surname><given-names>W</given-names></name><name><surname>Lichao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Inhibition of the replication of hepatitis B virus
<italic>in vitro</italic> by emodin</article-title><source>Med Sci Monit</source><year>2006</year><volume>12</volume><fpage>BR302</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16940925</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Rossum</surname><given-names>TG</given-names></name><name><surname>Vulto</surname><given-names>AG</given-names></name><name><surname>Hop</surname><given-names>WC</given-names></name><name><surname>Brouwer</surname><given-names>JT</given-names></name><name><surname>Niesters</surname><given-names>HG</given-names></name><name><surname>Schalm</surname><given-names>SW</given-names></name></person-group><article-title>Intravenous glycyrrhizin for the treatment of chronic hepatitis C: A double-blind, randomized, placebo-controlled phase I/II trial</article-title><source>J Gastroenterol Hepatol</source><year>1999</year><volume>14</volume><fpage>1093</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10574137</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vailati</surname><given-names>A</given-names></name><name><surname>Aristia</surname><given-names>L</given-names></name><name><surname>Sozze</surname><given-names>E</given-names></name><name><surname>Milani</surname><given-names>F</given-names></name><name><surname>Inglese</surname><given-names>V</given-names></name><name><surname>Galenda</surname><given-names>P</given-names></name></person-group><article-title>Randomized open study of the dose&#x02013;effect relationship of a short course of IdB 1016 in patients with viral or alcoholic hepatitis</article-title><source>Fitoterapia</source><year>1993</year><volume>64</volume><fpage>219</fpage><lpage>28</lpage></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poynard</surname><given-names>T</given-names></name><name><surname>Leroy</surname><given-names>V</given-names></name><name><surname>Cohard</surname><given-names>M</given-names></name><name><surname>Thevenot</surname><given-names>T</given-names></name><name><surname>Mathurin</surname><given-names>P</given-names></name><name><surname>Opolon</surname><given-names>P</given-names></name><etal/></person-group><article-title>Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration</article-title><source>Hepatology</source><year>1996</year><volume>24</volume><fpage>778</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">8855176</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Page</surname><given-names>T</given-names></name><name><surname>Connor</surname><given-names>JD</given-names></name></person-group><article-title>The metabolism of ribavirin in erythrocytes and nucleated cells</article-title><source>Int J Biochem</source><year>1990</year><volume>22</volume><fpage>379</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">2159925</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dusheiko</surname><given-names>G</given-names></name></person-group><article-title>Side effects of alpha interferon in chronic hepatitis C</article-title><source>Hepatology</source><year>1997</year><volume>26</volume><fpage>112</fpage><lpage>21</lpage></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valentine</surname><given-names>AD</given-names></name><name><surname>Meyers</surname><given-names>CA</given-names></name><name><surname>Kling</surname><given-names>MA</given-names></name><name><surname>Richelson</surname><given-names>E</given-names></name><name><surname>Hauser</surname><given-names>P</given-names></name></person-group><article-title>Mood and cognitive side effects of interferon-alpha therapy</article-title><source>Semin Oncol</source><year>1998</year><volume>25</volume><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">9482539</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyers</surname><given-names>CA</given-names></name><name><surname>Scheibel</surname><given-names>RS</given-names></name><name><surname>Forman</surname><given-names>AD</given-names></name></person-group><article-title>Persistent neurotoxicity of systemically administered interferon-alpha</article-title><source>Neurology</source><year>1991</year><volume>41</volume><fpage>672</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">2027482</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiranowska</surname><given-names>M</given-names></name><name><surname>Wilson</surname><given-names>TC</given-names></name><name><surname>Thompson</surname><given-names>K</given-names></name><name><surname>Prockop</surname><given-names>LD</given-names></name></person-group><article-title>Cerebral interferon entry in mice after osmotic alteration of blood-brain barrier</article-title><source>J Interferon Res</source><year>1989</year><volume>9</volume><fpage>353</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">2746023</pub-id></element-citation></ref></ref-list></back></article>